China: CDE Rejected 542 Drug Applications Last Year
Accestra Consulting’s Zhao Lu* looks back on a year in which China’s Center for Disease Evaluation (CDE) rejected a record-breaking number of drug applications, explores some of the main reasons…
CR Pharmaceutical Group Limited was set up in response to the requirement of the State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) to “create a state-owned pharmaceutical platform” in 2007. It is an integrated enterprise group combining pharmaceutical R&D, manufacturing and production, as well as marketing under one umbrella. Leveraging its strong industrial base leading competitive advantages, CR Pharma is striving to “become the leader in China’s pharmaceutical industry”. In 2013, both turnover and assets of the company exceeded HK$100 billion, and CR Pharma ranked second in terms of overall strength in China’s pharmaceutical industry. On October 28, 2016, China Resources Pharmaceutical Group Limited (3320HK) was officially listed on the Hong Kong Stock Exchange.
CR Pharma owns two grade-1 profit centers, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., as well as famous companies including Shandong Dong-E-E-Jiao Pharmaceutical Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., China Anhui World-Best Pharmaceutical Co., Ltd., and China Resources Pien Tze Huang Pharmaceutical Co., Ltd. Among them, CR Sanjiu (000999), CR Double-Crane, and Dong-E-E-Jiao (000423) are A-share pharmaceutical companies listed in China.
In the area of pharmaceutical manufacturing, CR Pharma is involved in natural medicine, Chinese medicine, chemical drugs, biological drugs and nutritional supplements. It ranked number one in the 2011 China Top 100 Pharmaceutical Manufacturing Enterprises, and owns well-known brands including “999”, “Double-Crane”, “Saike”, “Dong-E”, “Zizhu”, and “Yu Ting”.
In terms of retail and distribution, its business covers wholesale distribution of drugs, medical equipment, healthcare products, logistics, distribution, retail and supply chain value-added services. It ranks second among China’s pharmaceutical businesses and is the market leader in the areas of hospital drugs distribution and extended services, and modern logistics and distribution services in China.
CR Pharma possesses abundant and quality R&D resources, and strong independent innovation capabilities. It has established two national research centres for Chinese patent medicine and traditional Chinese gelatine medicine (Ejiao series), and numerous provincial level technology centres, serving as the R&D base for birth control and genital health drugs. It is leading the industry in pharmaceutical preparation and new pharmaceutical controlled-release technologies within China and is world-leading in its core R&D technology in pharmaceutical nucleoside intermediates. Through innovation and collaboration, CR Pharma will continue to focus on providing high-quality and reliable products and services to the public and will strive to become the market leader in China’s pharmaceutical industry.
Accestra Consulting’s Zhao Lu* looks back on a year in which China’s Center for Disease Evaluation (CDE) rejected a record-breaking number of drug applications, explores some of the main reasons…
China’s strict ‘dynamic COVID-zero’ policy, relying on lockdowns, mass-testing and border controls to stamp out COVID-19 outbreaks wherever they appear, has undoubtedly constricted the country’s economic growth and prompted uncommon…
DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021:…
A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR…
Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up…
China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell…
A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs,…
Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential…
Due in part to an increasingly encouraging regulatory environment, China continues to strive for progress in cell and gene therapies (CGT). In fact, according to a 2021 Nature study, CAR…
Writing in the May edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk China looks at the new drug approvals in China in 2021. Among other highlights, the…
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
See our Cookie Privacy Policy Here
